Mylan recalls batches of Nizatidine capsules after nitrosamine detected in API9 Jan 2020
The US arm of generic and specialty pharma company Mylan Pharmaceuticals has recalled three lots of its heartburn drug Nizatidine in capsule form amid fears of possible nitrosamine contamination.
The voluntary nationwide recall comes after trace amounts of the nitrosamine impurity N-Nitrosodimethylamine (NDMA) were detected in the active pharmaceutical ingredient (API) supplied by India-based Solara Active Pharma Sciences Ltd.
Mylan said it had recalled three lots of Nizatidine capsules, including the 150mg and 300mg strengths, which were distributed to wholesalers, mail order pharmacies, wholesale and retail pharmacies and a distributor between June 2017 and August 2018.
The company has so far not received any reports of adverse events related to these batches, it added.
The action marks the latest in a string of recalls prompted by the potential risk of nitrosamine impurities in medications that have rocked the API manufacturing sector over the last two years.
The US Food and Drug Administration first said it had detected NDMA in Angiotensin II receptor blockers used to treat blood pressure and heart conditions and heartburn drug, ranitidine, sold under the brand name Zantac among others, back in July 2018.
The drug regulator has asked manufacturers of nizatidine and ranitidine to test their products for NDMA and send samples in. It is also conducting ongoing investigations into the presence of nitrosamine in other drug products.
Meanwhile, the European Medicines Agency has asked manufacturers to complete a risk assessment of products potentially affected by 26 March this year.
NDMA, a chemical form of nitrosamine and generally found in water and foods, including processed meats dairy products and vegetables, is classified as a probable human carcinogen that could cause cancer.
Nizatidine is a histamine H2 receptor antagonist used to treat active duodenal ulcers and benign gastric ulcers as well as gastroesophageal reflux disease. It was first approved for medical use in 1987.
Pioneer in Phenylketonuria to begin clinical trial with gene therapy
15 Jan 2020
BMN 307 represents a potential third PKU treatment option from BioMarin and its second gene therapy clinical program.Read more
Catalent launches direct-to-patient clinical supply services
14 Jan 2020
Multiple options provide increased flexibility for sponsors.Read more
Biogen to acquire novel clinical-stage asset from Pfizer
14 Jan 2020
PF-05251749 complements the company’s pipeline of potential disease-modifying therapies for Alzheimer’s and Parkinson’s diseases.Read more
French regulator agrees to partial resumption of Tellomak trial patient recruitment
14 Jan 2020
The French National Agency for Medicines and Health Product Safety (ANSM) has agreed that Innate Pharma’s Tellomak (lacutamab) Phase II trial can resume recruitment of new patients with relapsed/refractory Sézary syndrome and mycosis fungoides (MF) in ...Read more
Lupin could face FDA regulatory action over Tarapur API facility
13 Jan 2020
India’s Lupin Pharmaceuticals warned Monday it could face regulatory sanctions from the US Food and Drug Administration over its Tarapur active pharmaceutical ingredient (API) manufacturing facility.Read more
Partnership formed to develop and commercialise ready-to-use medicine
13 Jan 2020
The product being developed will use proprietary drug formulation technology platform Arestat to deliver new reformulations of existing, complex products.Read more
ReadCoor to commercially launch spatial sequencing platform
10 Jan 2020
Platform gives researchers access to previously undiscovered data to guide evaluation and validation of new drug targets, pathogen identification, disease diagnosis, and the advancement of regenerative medicine.Read more
CPhI and AAPS partner to expand expert scientific content at CPhI North America
10 Jan 2020
CPhI and the American Association of Pharmaceutical Scientists (AAPS) today announced a partnership to expand the scientific content of activities sponsored by CPhI, including CPhI North America—the only event to bring the entire North American pharmac...Read more
New HQ for developer of world's first fully automated drug discovery platform
8 Jan 2020
End-to-end robotic platform provides biotechnology companies, pharmaceutical corporations and academic centres with cost-effective and reproducible drug discovery data.Read more
Catalent completes purchase of biologics fill-finish and oral solid dose facility
7 Jan 2020
Facility provides European customers with great biologics and oral dose capabilities that can help reduce time-to-market.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation